EPRX — EUPRAXIA PHARMACEUTICALS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1581178 ·
British Columbia, Canada
Last close
$7.46
Market Cap
$492.91M
52W High
$9.32
52W Low
$5.25
ADV30
848,505
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -18,103,173 | -14,486,955 | 139,907,536 | 52,426,167 | 10,233,774 |
| Mar 2026 | 0 | — | -15,957,045 | -12,653,431 | 145,353,342 | 58,500,024 | 9,165,681 |
| Dec 2025 | 0 | — | -16,162,620 | -16,711,252 | 86,150,008 | 80,563,482 | 5,703,915 |
| Sep 2025 | 0 | — | -6,883,100 | -6,361,367 | 92,349,055 | 88,959,281 | 3,905,493 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-32,695,894
Investing CF
$-80,471,420
Financing CF
$144,211,599
CapEx
$-746,856
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.89
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-182,233,405
Inventory
—
Receivables
$663,235
ST Investments
$80,378,789
EBIT TTM
$-47,779,125
Pretax Income TTM
$-44,463,021
Interest Exp TTM
$0
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -38,434,039 | -38,576,143 | 86,150,008 | 5,703,915 | 82,041,436 | -28,552,218 |
| Dec 2024 | 0 | -27,003,411 | -25,502,536 | 34,942,355 | 3,103,386 | 33,404,803 | -29,994,491 |
| Dec 2023 | 0 | -27,847,229 | -28,220,796 | 20,266,229 | 19,373,903 | 2,216,207 | -20,748,619 |
| Dec 2022 | 0 | -17,617,452 | -18,489,629 | 19,122,249 | 11,914,395 | 7,786,525 | -14,395,201 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARVN | ARVINAS, INC. | $492.94M | $7.64 | — |
| OVID | Ovid Therapeutics Inc. | $480.43M | $2.46 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $479.08M | $23.53 | — |
| ALT | Altimmune, Inc. | $507.69M | $2.61 | — |
| VREOF | Vireo Growth Inc. | $476.65M | $9.38 | — |
News headlines (Yahoo Finance, 1h cache)
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
2026-10-09 12:00 · Yahoo
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients
2026-09-30 16:27 · Yahoo
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
2026-09-30 12:00 · Yahoo
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
2026-09-12 07:56 · Yahoo
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
2026-09-08 12:00 · Yahoo
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
2026-08-13 12:00 · Yahoo
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
2026-08-11 21:21 · Yahoo
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?
2026-08-10 13:55 · Yahoo
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
2026-07-13 20:05 · Yahoo
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
2026-07-07 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.